<DOC>
	<DOCNO>NCT01961505</DOCNO>
	<brief_summary>Rheumatoid Arthritis ( RA ) autoimmune disease result chronic inflammatory disorder may affect many synovial joint , may cause serious disability . It confirm tripterygium extract effect anti-inflammatory , immunosuppressive cartilage protection . This prospective randomized control study evaluate efficacy safety external application compound tripterygium gel treat patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>External Therapy With Compound Tripterygium Gel Decreasing Disease Activity Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Documented diagnosis rheumatoid arthritis , define American Rheumatism Association 1987 Revised Criteria European League Against Rheumatism criterion ( 2009 ) . Patients must moderately severely active RA , DAS28 score 3.2 5.1 . If take disease modify antirheumatic drug ( DMARDs ) ( e.g.Methotrexate ) , subject must stable dose ≥ 3 month prior randomization . If take nonsteroidal antiinflammatory drug ( NSAIDs ) , subject must stable dose ≥ 4 week prior randomization . 16 65 year old , sign informed consent . Patients skin burst allergy . Patients sever disease Cardiovascular , brain , lung , liver , kidney hematopoietic system . Patients treat tripterygium , hormones biological agent . Patients treat DMARDs . Patients unwilling comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>